BRIEF-ContraVir to highlight clinical data from phase 2a study of tenofovir exalidex for treating hepatitis B
Feb 14 ContraVir Pharmaceuticals Inc -
* ContraVir to highlight clinical data from ongoing phase 2a study of tenofovir exalidex (TXL) for treating hepatitis B
* TXL showed comparable antiviral activity to viread and continues to be safe and well tolerated by HBV patients in study Source text for Eikon: Further company coverage: